MYUNGMOON Pharm co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 15, 2021 at 04:07 am
Share
MYUNGMOON Pharm co.,Ltd reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was KRW 35,198.77 million compared to KRW 32,151.4 million a year ago. Net loss was KRW 133.82 million compared to KRW 4,804.99 million a year ago. Basic loss per share from continuing operations was KRW 4 compared to KRW 174 a year ago. Basic loss per share was KRW 4 compared to KRW 174 a year ago.
For the nine months, sales was KRW 5,324.23 million compared to KRW 4,353.15 million a year ago. Net income was KRW 1,140.73 million compared to net loss of KRW 19,667.73 million a year ago. Basic earnings per share from continuing operations was KRW 34 compared to basic loss per share from continuing operations of KRW 709 a year ago. Basic earnings per share was KRW 34 compared to basic loss per share of KRW 709 a year ago.
MyungMoon Pharm. Co., Ltd. is a Korea-based company mainly engaged in the manufacture of pharmaceuticals. Its products include ethical (ETC) drugs and over the counter (OTC) drugs. Its ETC drugs include anesthetic agents, digestive system drugs, rheumatoid arthritis remedies, central nervous system drugs, circulatory drugs, anti-depressant agents, anti-diabetic agents, antibiotics, hormone agents, narcotics and drugs for dermatology systems. Its OTC drugs include antinauseant agents, hepatic agents, immunologic agents, antidiarrheal agents, skin external preparations, antiallergic agents, muscle relaxants, cold drugs and parasiticides. The Company is also involved in the operation golf courses. January 2, 2012, the Company completed the merger with its wholly owned subsidiary.